SEC Form 4 · accession 0001104659-16-147606
Syros Pharmaceuticals, Inc. · SYRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gerald E Quirk
Officer — Chief Legal Officer
Period of report
Sep 27, 2016
Accepted (ET)
Sep 29, 2016 · 5:11 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001556263
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $13.30 | Sep 27, 2016 | A | 105,000 | A | — | Sep 26, 2026 | Common Stock | 105,000 | 105,000 | D |
Explanation of responses
- F1The vesting commencement date ("Vesting Commencement Date") of the option is September 26, 2016. The option becomes exercisable as to 25% of the shares underlying the award on the twelve month anniversary of the Vesting Commencement Date, with the remainder vesting in equal monthly installments of 2.0833% of the shares underlying the award until the fourth anniversary of the Vesting Commencement Date, subject to Mr. Quirk's continued service as an employee through each applicable vesting date.